Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Sacituzumab tirumotecan (SKB264/MK-2870) in combination w... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study.
0
Authors
Wenfeng Fang
19 more
Wenfeng Fang
•
Qiming Wang
17 more
•
Li Zhang
Published
June 1, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to review
Share your thoughts on this paper...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Journal of Clinical Oncology
Topics
Medicine
Cancer Oncology
Internal Medicine
Organic Chemistry
Pulmonary And Respiratory Medicine
Show all topics
DOI
10.1200/jco.2024.42.16_suppl.8502
